Eurand Announces First Quarter 2008 Financial Results Conference Call

Corporate news announcement processed and transmitted by Hugin ASA.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------

AMSTERDAM, Netherlands, April 17, 2008 (PRIME NEWSWIRE) -- Eurand
N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops,
manufactures and commercializes enhanced pharmaceutical and
biopharmaceutical products based on its proprietary drug formulation
technologies, will host a conference call on Friday, May 9, 2008 at
8:30 AM ET to report its first quarter 2008 financial results. The
conference call will be hosted by Gearoid Faherty, Chief Executive
Officer, and Mario Crovetto, Chief Financial Officer.

Conference call schedule:

8:00 AM ET: First quarter 2008 financial results will be released

8:20 AM ET: To participate in the conference call:

-- U.S. Participants dial 1-877-407-0789

-- International Participants dial +1-201-689-8562

8:30 AM ET: Conference call begins promptly

Call Replay: A dial-up replay of the call will be available until
June 9, 2008. The Account Number is is: 3055,
Conference ID Number: 282168.

-- U.S. Participants dial 1-877-660-6853

-- International Participants dial +1-1-201-612-7415

A live web cast of the call will also be available from the Investor
Relations section on the corporate web site at www.eurand.com.
Following the live webcast, the archived version of the call will be
available at the same URL until June 9, 2008.

About Eurand

Eurand is a specialty pharmaceutical company that develops,
manufactures and commercializes enhanced pharmaceutical and
biopharmaceutical products based on its proprietary drug formulation
technologies. Eurand has had four partnered products approved by the
FDA since 2001 and has a pipeline of product candidates in
development for itself and its collaboration partners. Eurand has
completed two phase III clinical trials on its lead product
candidate, Zentase(tm) (EUR-1008), intended for the treatment of
Exocrine Pancreatic Insufficiency and has submitted an NDA for this
product which has been granted priority review. Eurand's technology
platforms include bioavailability enhancement of poorly soluble
drugs, customized release, taste-masking/fast-dissolving formulations
and drug conjugation.

Eurand is a global company with facilities in the USA and Europe. For
more information, visit Eurand's website at www.eurand.com.

This release, and oral statements made with respect to information
contained in this release, constitutes forward-looking statements.
Such forward-looking statements include those which express plan,
anticipation, intent, contingency, goals, targets or future
development and/or otherwise are not statements of historical fact
including, but not limited to our plans for our NDA filing,
enrollment and future plans for our clinical trials, progress of and
reports of results from clinical studies, clinical development plans
and product development activities. The words "potentially", "could",
"calls for" and similar expressions also identify forward-looking
statements. These statements are based upon management's current
expectations and are subject to risks and uncertainties, known and
unknown, which could cause actual results and developments to differ
materially from those expressed or implied in such statements.
Factors that could affect actual results include risks associated
with the possibility that the FDA refuses to approve our NDA; the
outcome of any discussions with the FDA; and unexpected delays in
preparation of materials for submission to the FDA as a part of our
NDA filing. Forward-looking statements contained in this press
release are made as of this date, and we undertake no obligation to
publicly update any forward-looking statement, whether as a result of
new information, future events or otherwise. Actual events could
differ materially from those anticipated in the forward-looking
statements.

CONTACT:
Eurand N.V.
Mario Crovetto, Chief Financial Officer
+39 02 95428 521
mario.crovetto@eurand.com

The Ruth Group
Nick Laudico
646-536-7030
nlaudico@theruthgroup.com
Elizabeth Scott
646-536-7014
escott@theruthgroup.com

--- End of Message ---

Eurand N.V.
845 Center Drive Vandalia, Ohio USA

WKN: A0MSPK; ISIN:
NL0000886448;
;